Adjunctive daratumumab can induce rapid remission in acquired haemophilia A with poor prognostic markers

Haemophilia. 2023 Nov;29(6):1649-1652. doi: 10.1111/hae.14850. Epub 2023 Sep 4.

Authors

Chatphatai Moonla^{1

2}, Chantana Polprasert^{1

2}, San Krittikarux³, Nuanrat Cheerasiri^{1

2}, Benjaporn Akkawat^{1

2}, Ponlapat Rojnuckarin^{1

2}, Noppacharn Uaprasert^{1

2}

Affiliations

¹ Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
² Center of Excellence in Translational Hematology, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
³ Department of Medicine, Sakaeo Crown Prince Hospital, Sakaeo, Thailand.

PMID: 37665794
DOI: 10.1111/hae.14850

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal / therapeutic use
Hemophilia A* / drug therapy
Humans
Prognosis

Substances

daratumumab
Antibodies, Monoclonal

Supplementary concepts

Factor 8 deficiency, acquired